Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown133%
not_yet_recruiting267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

NCT05202288
not_yet_recruitingphase_3

EBOla Post-Exposure Prophylaxis

NCT06841614
unknownphase_2

Prophylaxis Vaccine Antibodies Ebola

NCT04822376

Clinical Trials (3)

Showing 3 of 3 trials
NCT05202288Phase 2

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Not Yet Recruiting
NCT06841614Phase 3

EBOla Post-Exposure Prophylaxis

Not Yet Recruiting
NCT04822376Phase 2

Prophylaxis Vaccine Antibodies Ebola

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3